Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jovanovic (Belgrade, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), . Stoeva (Sofia, Bulgaria), B. Jovkovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Belgrade, Republic of Serbia), M. Vašáková (Prague, Czech Republic). Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. 3391

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF Source: Eur Respir J 2015; 46: 1217-1221 Year: 2015 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Assessment of blood biomarkers in patients with IPF under antifibrotic therapy Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 What influences patient choice of antifibrotic treatment in IPF? Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Adverse effects analysis results during anti-TB treatment among hemodialysis patients Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 How to manage immune-related adverse effects in lung cancer patients under immunotherapy Source: CME Online 2019 Year: 2018 Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis. Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Monitoring anti-inflammatory treatments in IPF and related disorders Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments Year: 2004